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The means by which pre-B lymphoid cells are transformed to malignancy by 
Abelson murine leukemia virus (A-MuLVy are still unclear. Essential for activity 
of this rapidly transforming virus is a transduced section of a cellular gene, c-abl, 
labeled v-abl in the viral genome, that replaced classical  retroviral pol, env, and 
a portion of gag DNA sequences (1). The replication-defective A-MuLV depends 
upon coinfection with the competent parent virus,  Moloney murine leukemia 
virus (M-MuLV), which supplies genes encoding reverse transcriptase (pol) and 
viral structural proteins (gag,  env)  necessary for assembly of new viral particles 
(2). The gag-abl  fusion protein encoded by the A-MuLV genome locates at the 
inner aspect of the plasma membrane (3) and is a tyrosine phosphoprotein kinase 
capable  of phosphorylating itself (4)  and  cellular proteins  (5).  Several  known 
oncogenes (e.g.,  v-src)  share  this  behavior  with  v-abl  (6-11).  Although v-abl 
expression is necessary for A-MuLV pre-B cell neoplastic transformation, it does 
not appear  to  be  sufficient for autonomous growth: early, in  vitro A-MuLV- 
infected bone marrow pre-B cells express high levels of v-abl,  but their growth 
is nevertheless dependent on  bone marrow-derived stromal feeder layer cells 
(12).  Later,  without  apparent  change  in  v-abl  expression,  malignant  clones 
emerge that grow in a feeder layer-independent fashion. These later malignant 
clones, but not most v-abl + cells, which predominate in the premalignant period, 
express  a  transformation-associated B  lineage tumor antigen detected by  the 
monoclonal antibody 6C3 (mAb 6C3) (13  and Tidmarsh, Whitlock, and Weiss- 
man, manuscript in preparation). 
Previously (13), we demonstrated that the antigen detected by mAb 6C3 (6C3 
Ag)  was present  on  a  moderately abundant  160  kD  cell-surface glycoprotein 
(gpl606c3) on the surface of all A-MuLV established cell lines and some sponta- 
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neous B lineage leukemias, but was absent from A-MuLV-transformed fibroblasts 
(13).  In  addition,  gpI60 ~c~  is  not  the  product  of genes  contained  in  the  A- 
MuLV/M-MuLV complex. Because of the correlation between expression of this 
nonviral antigen and the transformed phenotype, we proposed that a  high level 
of expression of gpl60 ~c3 not only identifies the neoplastic state but may play a 
central role as a normal cellular gene product in the oncogenic process. Thus, it 
became important to determine (a) if the antigen is expressed on any nontrans- 
formed,  normal  lymphoid cells,  and  (b) if a  positive correlation  exists between 
A-MuLV transformation  of lymphoid cells in  vivo and  high  level expression of 
this antigen. 
Towards this goal, we developed more sensitive techniques to analyze lymphoid 
cells for the presence of the antigen before and after infection with A-MuLV in 
vivo. Using these techniques,  we identify here normal cells that display very low 
levels of the 6C3 Ag on their surface compared with A-MuLV-transformed cells. 
We  document  a  tissue-specific  increase  in  cell  surface  antigen  expression  in 
Abelson-diseased  mice.  Furthermore,  in  such  mice  we  demonstrate  that  cells 
bearing high levels of this antigen are neoplastically transformed and specifically 
coexpress differentiation markers representative of pre-B cells. 
Materials and  Methods 
Cells.  The A-MuLV in  vitro lymphoma cell lines LI-2 and 2M3  and the A-MuLV- 
transformed,  non-virus-producing fibroblast line,  ANN-I, were originally provided by 
Naomi  Rosenberg  (Tufts  University,  Medford,  MA).  The  rat  IgG2a  mAb-producing 
hybridoma, 6C3,  was developed as described earlier (13);  the control rat IgG2a mono- 
clonal hybridoma R7D4 was obtained courtesy of Ron Levy (Stanford University). mAb 
R7D4 recognizes an idiotypic determinant on a human B-cell lymphoma. The anti-B220 
monoclonal hybridoma 6B2 and the anti-ThB monoclonal hybridoma were kindly pro- 
vided by Robert Coffman (DNAX Research Institute, Palo Alto, CA). Production of the 
rat IgG2a mAb 31-11, specific for the constant region of mouse Thy-1, was described 
elsewhere (14).  mAb  10-4.22, a  mouse IgM antibody directed towards mouse IgD, was 
obtained  from  the  American  Type Culture  Collection,  Rockville,  MD.  All  cells  were 
grown in Dulbecco's modified Eagle's medium or RPMI  1640 (JR Scientific, Woodland, 
CA) with 10% fetal calf serum, and 3 x  10 -5 M 2-mercaptoethanol. 
Virus.  Virus was harvested from confluent, clonal M-MuLV-producing cells originally 
provided by O. N. Witte (University of California, Los Angeles). This virus was then used 
to rescue the A-MuLV genome from a confluent culture of ANN-1. After  16 h, culture 
supernatant was harvested, filtered through a 0.45 ~zm filter, and stored at -70°C until 
use. This stock was titrated in susceptible BALB/c mice. All mice developed typical signs 
of Abelson  disease  3-5  wk after retroorbital  intravenous  injection  of 0.1  ml  of virus, 
whereas only 30% became symptomatic after injection with 0.025 ml. An injection of 0.1 
ml was used throughout this study. 
Mice.  All mice used for induction of Abelson tumors were BALB/c and no older than 
4  wk at the time of injection.  All  normal mice were 3-8-wk-old, BALB/c mice bred in 
our colony. There is no observed difference in A-MuLV susceptibility between sexes (15), 
so both males and females were used for injection. There was an observed difference in 
the quantity of antigen  in the thymus of female vs. male normal young mice. Where a 
comparison has been made, animals are sex matched. 
Immunofluorescence Reagents.  mAb was purified from Nu/Nu mouse ascitic fluid using 
DEAE Affi-gel Blue chromatography (Bio-Rad Laboratories, Richmond, CA) (16).  Both 
rabbit and goat anti-rat second-stage reagents were used without any difference in result. 
Rabbit anti-rat serum was produced in our laboratory. Goat anti-rat was obtained from 
PeI-Freez Biologicals (Rogers, AR).  Immunoglobulin was purified by protein A chroma- TIDMARSH  ET  AL.  1423 
tography.  Purified  immunoglobulin  was  coupled  to  fluorescein  isothiocyanate  by  the 
established  method of Goding (17),  after further purification  to high specificity for rat 
immunoglobulin by several passages over a  Sepharose  4B (Pharmacia,  Inc., Piscataway, 
NJ)-coupled mouse immunoglobulin column. As a further precaution, the fluoresceinated 
second-stage  reagent,  when  used,  contained  10%  (final  concentration)  normal  mouse 
serum.  All antibodies  and  the  normal  mouse serum  were centrifuged  for  15  min  in  a 
Beckman  Airfuge  (Beckman  Instruments,  Inc.,  Irvine,  CA) at  20  psi  before  use.  For 
detection  of biotinylated  reagents,  Texas  Red-coupled  avidin  (Cappel  Laboratories, 
Cochranville, PA) was used as a second-stage reagent. 
Cell Suspensions.  Lymphoid organs, both primary (thymus and femoral bone marrow) 
and secondary (lymph nodes and spleen),  were removed from sacrificed animals.  After 
scalpel  sectioning  of both  ends  of all  bones,  marrow  plugs  were  gently  removed  via 
expulsion with a  syringe of cold suspending medium (Hank's balanced salt solution,  5% 
fetal calf serum,  0.1%  NAN3).  Other organs were teased  apart with  forceps and  gently 
filtered  through  a  200-gauge  stainless  steel  screen.  Bone  marrow  suspensions  were 
routinely centrifuged at room temperature  (20 min,  2,000  rpm) underlayed with Lym- 
pholyte M (Cedarlane Laboratories Ltd., Ontario, Canada). Cell counts were determined 
in the presence of trypan blue to exclude dead cells or with Turk's solution to exclude 
nonnucleated cells (bone marrow). 
Immunofluorescence Staining.  106 cells of each cell suspension were placed in a  Falcon 
No. 2052 tube (Becton, Dickinson & Co., Cockeysville, MD) tube for each antibody. After 
a  centrifugation  wash through newborn calf serum and aspiration  of supernatant,  each 
pellet was resuspended in 0.025 ml appropriately diluted test antibody solution for  10- 
15  min  on ice, before a  second wash.  If a  second stage reagent  was required,  samples 
were resuspended in 0.025 ml appropriately diluted reagent and incubated 10 min on ice 
before staining dead cells with propidium  iodide as described before (18). After a  third 
wash, each sample was brought up in 0.1  ml suspension medium for FACS analysis. 
FACS Analysis.  Fluorescence-activated cell sorter (FACS) analysis of immunofluores- 
cence was accomplished using a  FACS II (Becton Dickinson Immunocytometry Systems, 
Mountain View, CA) for one color and a modified dual laser FACS for two color analysis 
(17). This machine was made available through the FACS shared users group at Stanford 
University. 
Analysis oflmmunofluorescence Data.  After collection of mAb R7D4 background fluo- 
rescence data on one sample of each lymphoid tissue, a  fluorescence gate was chosen to 
include ~99% of the cells in that sample below the chosen gate. This gate is termed the 
tissue  background  gate.  Once  established,  the  tissue  background gate  was used  in  the 
analysis  of all  stainings  of that  tissue  to  avoid  introducing  bias  to  the  analysis.  The 
percentage of mAb 6C3-positive cells for each tissue staining is defined as: (percentage 
cells exceeding tissue background gate in mAb 6C3 sample) -  (percentage cells exceeding 
tissue background gate in mAb R7D4 sample). Mean fluorescence was obtained only for 
those cells in the test sample that fell above the chosen gate. It should be noted that the 
calculated percentage is not an absolute value but only a number to be used for comparison 
relative  to  percentages  obtained  by  the  same  procedure,  for  the  same  tissue,  from a 
different mouse. 
For statistical  comparison of values obtained in this way, we used the  Mann-Whitney 
rank test. Here, values from two groups of stainings, e.g., bone marrow from normal and 
M-MuLV-injected mice, are ranked together in order of their relative value. A serial rank 
number is then assigned to each value (1  through combined total n of both groups). The 
actual value is lost and has no further meaning in the analysis. The summed rank of each 
group is compared mathematically, and, based on the number of samples in each group, 
a statement of confidence can be made as to whether the mean values of the two groups 
are different. 
Radioimmunoassay.  500/.tCi  125I (New England Nuclear, Boston, MA) was coupled to 
10  #g of purified  mAb 6C3  or  R7D4  using chloramine  T.  Briefly,  0.005,0.02  ml  of 
antibody in phosphate-buffered saline was added to a mixture of 0.01  ml  1 M phosphate 
buffer, pH 7.4 and 0.01  m1125I diluted previously to 1 mCi/0.02 ml with 0.5 M NaOH. 1424  B  LINEAGE  A-MuLV  TRANSFORMATION  ANTIGEN 
At t =  0 at room temperature, 0.002 ml ofa 5 mg/ml solution of chloramine T  (Eastman 
Kodak Co., Rochester, NY) was added and the reaction allowed to proceed for 1 min. At 
that time, 0.002 ml of a 5 mg/ml solution of sodium metabisulfite was added to stop the 
reaction. 0.07 ml of phosphate-buffered saline supplemented with 5% newborn calf serum 
was added and the mixture applied to a 0.5 ml column of Sephadex G-25 (Pharmacia, 
Inc., Piscataway, NJ) prewashed with phosphate-buffered saline/5% newborn calf serum. 
Fractions with  detectable radioactivity were collected to a  total  volume of 0.3  ml.  A 
measured volume of each labeled antibody was analyzed for radiation using a Beckman 
Biogamma counter (Beckman Instruments, Inc.). This analysis was performed so that an 
equal quantity of counts per minute from labeled mAb 6C3 or R7D4 could be used in 
the subsequent binding studies. Triplicate samples of 106 cells from bone marrow, spleen, 
thymus, or a log phase culture of L 1-2 were incubated in separate wells of a microtiter 
plate (Dynatech Laboratories, Inc.,  Alexandria,  VA) for 20  min  on ice, suspended  in 
0.025 ml of control or test antibody. 125I-coupled mAb 6C3 had been previously titrated 
to a binding plateau on  10 6 L1-2 cells. After four washes with ice-cold phosphate-buffered 
saline/5% newborn calf serum, the microtiter plate was dried under a heat lamp and the 
individual wells cut out before determining bound counts per minute. The mean count 
from triplicate samples and the standard error of the mean are presented. 
Agar Colony Assay.  Bone marrow cells were obtained from mice that bad previously 
been injected intravenously with A-MuLV and showed typical Abelson disease symptoms. 
After FACS analysis  of indirect mAb 6C3 immunofluorescence, appropriate gates were 
set on the FACS machine to sort the brightest 25% staining cells from the dimmest 25%. 
These cells were then compared for their ability to grow in agar as originally described 
by Rosenberg and Baltimore (19). 
Results 
6C3 Ag Is Present at Low Levels on Cells Suspended from Normal Lymphoid  Tissue, 
Most Predominantly Bone Marrow and Thymus.  It seemed unlikely that an antigen 
such as that recognized by mAb 6C3, expressed at high levels on the surface of 
pre-B and B cell lymphomas, would be absent from all normal tissues. To search 
for expression of the 6C3 Ag by normal cells we began by using a more sensitive 
techniqueiFACS  analysis of indirect immunofluorescence on cell suspensions-- 
than  used  previously  (13).  Expecting  extremely  low-level  expression  of  the 
antigen, we controlled for mAb isotype as well as for purification technique and 
protein  concentration  for  the  staining.  Fig.  1A  displays  representative  FACS 
plots comparing mAb  6C3-specific and mAb R7D4 background stainings on a 
normal bone marrow cell population. 
Each  of the  eight  stainings  on  untreated  BALB/c  bone  marrow  yielded  a 
similar result. Table I gives numerical data obtained from comparable immuno- 
fluorescence stainings  of three  groups  of mice.  Based  on  these  numbers,  the 
appropriate background control, and the high reproducibility, we conclude that 
there exists a subpopulation of normal BALB/c bone marrow cells that display a 
low  level of 6C3  Ag.  We  designate  these  cells  6C3Ag j° by comparison  to  the 
mean indirect mAb 6C3 immunofluorescence of the Abelson lymphoma cell line 
(L1-2), which is designated 6C3Ag hl. 
Additionally,  the  normal  female  BALB/c  thymus  contains  a  population  of 
6C3Ag  l° cells. Fig. 2A illustrates FACS plots comparing mAb R7D4 background 
with mAb 6C3-specific staining.  Again, each of the four experiments yielded a 
nearly  identical  result.  Analysis  done  on  normal  lymph  node and  spleen  cells 
shows that these tissues do not contain levels of the antigen distinguishable from 
the background level. TIDMARSH  ET  AL. 
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FIGURE  1.  mAb 6C3 immunofluorescence of bone marrow cells from normal and A-MuLV- 
infected  animals. Representative  FACS-generated  profiles  comparing  mAb  6C3-specific 
(  ) and mAb R7D4 (-- _) background immunofluorescence staining on bone marrow cells 
from a normal (A) or an Abelson-diseased (B) BALB/c mouse. Cell surface-bound mAb was 
detected using a fluorescein isothiocyanate-conjugated  anti-rat immunoglobulin. The vertical 
line in A represents the tissue background gate, described in Materials and Methods, used for 
numerical analysis of data in Table I. 
To  quantitate  the  amount  of 6C3  Ag  found  in  normal  lymphoid  tissue,  we 
coupled  125I directly  to  purified  mAb  6C3  and  mAb  R7D4,  as  outlined  in 
Materials and  Methods,  and  used the labeled antibodies in a  direct cell-binding 
radioimmunoassay.  Fig.  3  depicts a  graph  comparing mAb R7D4-specific and 
mAb 6C3-specific radioactivity bound to either normal lymphoid or L1-2 cells. 
Normal spleen  bound  a  barely detectable  level of mAb 6C3  while  the  thymus 
bound more than bone marrow; both bone marrow and thymus bound significant 
levels of Mab 6C3. 
A-MuLV  Infection  Leads  to  the  Appearance  of 6C3Ag  hi  Bone  Marrow  Cells  in 
Susceptible  Mouse Strains.  Infection of 3-4-wk-old BALB/c mice with A-MuLV 
caused  an  acute  lymphoma within  3-5  wk  that  was  rapidly  lethal.  Hind  limb 
paralysis is a  confirming diagnostic  sign  (15).  In  all  lymphoid organs analyzed 
from diseased mice, an altered distribution of the 6C3 Ag was observed. 6C3Ag  h~ 
cells,  never  found  in  normal  animals,  appeared  in  the  bone  marrow.  In  the 
thymus of diseased animals, 6C3Ag  t° cells were decreased in number compared 
with normal counterparts while 6C3Ag  hi cells were never observed. Figs.  1 B and 
2B  each  compare  FACS  plots  of  mAb  6C3  and  R7D4  immunofluorescent 
stainings on bone marrow and thymus cells, respectively, of an animal previously 1426  B  LINEAGE  A-MuLV  TRANSFORMATION  ANTIGEN 
TABLE  I 
Summary of mAb 6C3 Immunofluorescence 
Percentage mAb 6C3-positive cells in  Mean fluorescence (above 
Tissue  mice infected with:  background) 
A-MuLV  None  M-MuLV  A-MuLV  None  M-MuLV 
Bone marrow  50.7  5.9  12.9  16.1  2.7  3.5 
(22.6-72)  (3.5-9.4)  (9-17.3)  (9.5-22.2)  (2.2-3.1)  (3.2-4) 
Thymus  15.9  31.8  40.6  1.5  1.2  1.2 
(7.8-27)  (28-36.8)  (26.6-53)  (1-2)  (1-1.3)  (1-1.4) 
Spleen  16.6  1.8  0  13.6  NA  NA 
(9.3-28.9)  NA  NA  ( 12.1 - 14)  NA  NA 
Lymph nodes  16.7  0.07  0  9.1  NA  NA 
(0-43.9)  NA  NA  (8.5-10)  NA  NA 
LI-2  100  NA  NA  39  NA  NA 
100  NA  NA  (29-45)  NA  NA 
Lymphoid tissue distribution of the transformation-associated antigen recognized by mAb 6C3  in 
normal,  M-MuLV-infected, and A-MuLV-infected mice.  Data  represent average values (ranges in 
parenthesis).  Indirect immunofluorescent stainings were performed as  described in  Materials and 
Methods on cells suspended from the indicated tissues.  Positively staining cells were determined as 
those  exceeding background  mAb  R7D4  staining.  After  gating  for  mAb 6C3-staining cells,  we 
derived  a  mean  fluorescence  for  the  population.  Only an  approximate  comparison  of the  mean 
fluorescence data is practical because this data was collected on two different FACS machines. NA, 
not applicable. 
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FIGURE  2.  mAb 6C3 immunofluorescence of tbymocytes from normal and A-MuLV-infected 
animals.  Representative  FACS-generated  profiles comparing mAb 6C3-specific  (  )  and 
mAb R7D4  background (---)  immunofluorescence staining on thymocytes from a  normal 
(A) or an Abelson-diseased (B) BALB/c mouse. Cell surface-bound mAb was detected using 
fluorescein isothiocyanate-conjugated anti-rat immunoglobulin. The vertical line in A repre- 
sents tire tissue background gate used for analysis of data. TIDMARSH  ET  AL.  1427 
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FIGURE 3.  Normal lymphoid tissue mAb 6C3 radioimmunoassay. A whole cell radioimmu- 
noassay was performed to quantitate the transformation-associated  antigen recognized by mAb 
6C3 on the surface of normal lymphoid cells and the A-MuLV cell line, L1-2. As described in 
Materials and Methods, both mAb 7D4 and 6C3 were purified on DEAE Affi-gel blue and 
subsequently labeled with ]~5I. At 0 °C, 2 x  108 cpm of either labeled antibody was incubated 
with triplicate samples of 106 cells. After four washes with ice-cold phosphate-buffered saline, 
cell pellets were analyzed for bound gamma radiation. Note the log scale for this plot. 
infected with A-MuLV. The numerical analysis of all experiments is displayed in 
Table I. 
Most importantly,  the bone marrow of all  eight overtly lymphomatous mice 
contained a  subpopulation of cells whose density of mAb 6C3 staining approxi- 
mates that of the Abelson lymphoma, L 1-2 (6C3Ag  hl cells). A  rough correlation 
was observed between the severity of the disease symptoms and the percentage 
of 6C3Ag h~ cells  in  the  bone  marrow.  In  addition,  five of six  enlarged  lymph 
nodes and four of four enlarged spleens from the mice contained a subpopulation 
of 6C3Ag hi cells.  Further analysis of the thymus staining data  showed that  the 
percentage of 6C3Ag I° cells was actually decreased from that found in the average 
normal thymus (Table I); 6C3Ag  hl cells were never observed. This tissue distri- 
bution  of the  6C3  Ag  in  A-MuLV-infected  animals  generally correlates  with 
previous pathological analyses of the disease (15, 20). 
Appearance  of 6C3Ag  hi  Cells  in  lnfected  Mice  Is  Dependent  on  A-MuLV  and 
Independent of the Helper, M-MuLV.  As noted earlier, Abelson virus is defective 
for viral production and thus requires a  competent helper virus for production 
of new virus particles (2). It was, therefore, crucial to test whether the observed 
tissue-specific amplification of surface 6C3 Ag expression was A-MuLV depend- 
ent or was due to the helper virus, M-MuLV, used to prepare the A-MuLV stock. 
Culture supernatants from either clonal M-MuLV-producing cells or from ANN- 
1 cells superinfected with M-MuLV were injected intravenously into susceptible 
mice. Lymphoid tissues were removed and analyzed by indirect immunofluores- 
cence 3-4  wk  after injection,  the approximate  time of onset  for symptoms of 
Abelson disease. 
The data from this experiment are incorporated into Table I. None of the M- 
MuLV-infected mice developed a subpopulation of 6C3Ag  hi cells in any lymphoid 1428  B  LINEAGE  A-MuLV  TRANSFORMATION  ANTIGEN 
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FIGURE 4.  Two-color bone marrow cell immunofluorescence. Two-parameter immunofluo- 
rescence stainings were performed on bone marrow cells from either a normal BALB/c mouse 
(solid bars) or a BALB/c mouse previously infected with A-MuLV (hatched bars). Fluorescein 
isothiocyanate-coupled  mAb 6C3  was used to identify cells expressing the  transformation- 
associated antigen; biotinylated ThB, 6B2, anti-Thy-1, or anti-delta mAb were used to define 
these cells further.  Texas Red-labeled avidin was used to detect cells with bound biotinylated 
antibody after unbound antibodies were removed by centrifugation through fetal calf serum. 
The normal bone marrow  sample was determined  to have 19.6% ThB  ÷ cells, 32.9% 6B2 ÷ 
cells, 9.1% Thy- 1  +  cells, and 16.3  % delta-positive cells. These percentages agree with published 
data (21). 
organ  tested.  In addition,  5-6  mo after injection  we analyzed  the  thymus and 
bone  marrow  of lymphomatous  mice  by  radioimmunoassay  (data  not  shown). 
The data confirm a  previous finding (13) that the 6C3  Ag is not present on M- 
MuLV-transformed lymphoid (presumably T) cells. We conclude that the ampli- 
fication of the surface 6C3 Ag observed in the Abelson-diseased state is depend- 
ent  on  A-MuLV  and  independent  of infection  with  the  slowly  transforming 
parent retrovirus,  M-MuLV. 
However, these data show that M-MuLV alone can induce a significant increase 
in the percentage of 6C3Ag I° cells in bone marrow. Using the Mann & Whitney 
rank test, we can conclude with >99% confidence that the percentage of 6C3Ag I° 
cells in  bone  marrow was  increased  by injection  of M-MuLV  alone.  M-MuLV 
increased  the  number  of 6C3-positive  bone  marrow cells  without  altering  the 
surface  antigen  level  of each  cell,  based  on  mean  fluorescence.  Although  the 
average percentage of 6C3Ag ~° cells in the thymus appears to be increased after 
infection with  M-MuLV,  the increase and the sample size are not great enough 
to conclude this with >95%  confidence. 
6C3Ag  hi  In  Vivo-derived  A-MuLV  Bone  Marrow  Cells  Bear  Surface  Markers 
Characteristic  of  Early Pre-B Cells.  Fig. 4 displays data obtained by two parameter 
immunofluorescence  analysis  of  in  vivo  A-MuLV-infected  and  normal  bone 
marrow cells.  Fluorescein  isothiocyanate-coupled  mAb 6C3  was used to deter- 
mine cells bearing the transformation-associated 6C3 Ag, while biotinylated anti- 
Thy-1, -ThB, -IgD heavy chain (anti-delta), and 6B2 (anti-B220)  mAb were also 
used  to  phenotype  this  subpopulation.  In  normal  mouse  bone  marrow,  6B2 
marks all known pre-B and  B cells; ThB marks only late pre-B and  B cells, and TIDMARSH  ET  AL.  1429 
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FICURE 5.  mAb 6B2 vs. 6C3 two-parameter immunofluorescence  of bone marrow cells from 
normal and A-MuLV-infected  mice. Two-color immunofluorescence  stainings were performed 
on bone marrow cells from either a normal BALB/c mouse (A) or a BALB/c mouse previously 
infected with A-MuLV (B). As in Fig. 4, fluorescein isothiocyanate-coupled mAb 6C3 was 
used to identify cells expressing the transformation-associated  antigen; biotinylated mAb 6B2 
was used to define the B220  ÷ cells. Texas Red-labeled avidin was used to detect cells with 
bound biotinylated antibody after unbound antibodies were removed by centrifugation. 
delta,  only  mature  B  cells  and  Thy-l,  mainly  T  cells  (21).  Infection  with  A- 
MuLV resulted  in  the appearance of 6C3AghLbearing cells that were homoge- 
neous with respect to the other lymphoid markers.  All  6C3Ag  hi cells also bore 
the 6B2 antigen but lacked ThB, Thy-1, and delta surface antigen expression, a 
phenotype characteristic of early pre-B cells (Fig.  4).  Fig.  5, A and B  compares 
representative mAb 6B2 vs.  6C3 two-color FACS plots of normal and Abelson- 
diseased bone marrow, respectively. Although the 6C3Ag  I° cell in normal bone 
marrow are apparently equally distributed in the B220  + and B220- fractions, in 
Abelson-diseased mice the B220  + cells alone contain the 6C3Ag  hi cell population. 
This phenotype has been found on four of four tumors for B220 and two of two 
tumors  for  the  other  markers  and  it  agrees  with  the  pre-B  cell  phenotype 
observed for most A-MuLV-derived tumors. 
6C3Ag Marks  the  Transformed Cell Population in the Bone Marrow of Animals 
Infected with A-MuLV.  Because of the absolute correlation between overt Abel- 
son  disease  and  the  appearance  of 6C3Ag  h~  cells  in  bone  marrow,  it  seemed 
reasonable to test whether 6C3Ag  hi cells are transformed, as assayed by in vitro 
agar clonability (19). Cells were FACS sorted for the 6C3 Ag from bone marrow 
cells  pooled  from  three  animals  with  overt  Abelson  disease.  Fig.  6  shows  the 1430  B  LINEAGE  A-MuLV  TRANSFORMATION  ANTIGEN 
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FIGURE 6.  Agar colony assay of bone marrow cells sorted by FACS for the 6C3 Ag from A- 
MuLV-infected mice.  Autonomous growth capacity of bone marrow cells  from A-MuLV- 
infected mice was assessed in  relation  to  their expression of the transformation-associated 
antigen recognized by  mAb 6C3.  As described in  the text,  bone marrow cells from mice 
previously infected with A-MuLV were removed, indirectly tagged with rnAb 6C3, and FACS 
sorted for the  25%  highest and  25%  lowest antigen-expressing cells.  The  inset gives the 
ungated plot derived before sorting. Both populations were plated in agar at 37°C for 10 d 
before enumeration of  colonies. For comparison, A-MuLV established cell lines were included. 
(*) Colonies too numerous to count (900-1,000). 
results of this experiment.  A comparison of the number of colonies reveals that 
6C3Ag  hi cells are 100-fold more likely to form an agar colony than cells with low 
or no surface antigen. We conclude that mice with symptoms of Abelson disease 
have a  subpopulation of transformed  cells in their bone marrow and that these 
cells express higher levels of surface 6C3 Ag than found on normal bone marrow 
cells. 
Discussion 
The evidence presented here leads us to conclude that the 6C3 Ag is present 
at low levels on the surface of a  subset of normal  lymphoid cells in the thymus 
and bone marrow. This has been shown by FACS analysis ofimmunofluorescence 
(Figs.  1A and  2A) and  radioimmunoassay  (Fig.  3).  It will  be important  to test 
whether these 6C3Ag  j° cells express this antigen by endogenous synthesis rather 
than by passive adsorption. Elsewhere we show that a subset of dendritic stromal 
cells in the thymus express very high  levels of the 6C3  Ag (Adkins,  Tidmarsh, 
and  Weissman,  manuscript  in  preparation).  In  addition,  clonal  bone  marrow 
stromal cell lines that support the growth and differentiation of pre-B cells to B 
cells express the 6C3 antigen (unpublished observations). All attempts to immu- 
noprecipitate  labeled protein  from  thymocytes metabolically labeled with  high 
specific activity, radioactive amino acids with mAb 6C3 have failed whereas mAb 
6C3  immunoprecipitated  gpl606c3 from a  number of L1-2  cells displaying,  in 
aggregate,  less surface 6C3 Ag (Adkins,  Tidmarsh,  and  Weissman,  manuscript 
in  preparation).  We  propose  that  the  transfer  of the  6C3  Ag  from  closely 
associated 6C3Ag  h~ thymic stromal cells to thymocytes during preparation of cell 
suspensions might account for the detection of 6C3Ag  ~° thymocytes. This  type 
of adsorption is known to occur for Ia antigens within the thymus (22). TIDMARSH  ET  AL.  1431 
Prior infection of susceptible hosts with  A-MuLV leads to an  increase in  the 
amount  of this  antigen  in  bone  marrow,  lymph  nodes,  and  spleen,  but  not 
thymus.  This  increase  in  total  amount  of 6C3  Ag can  be ascribed to both  an 
increase in  the number of cells bearing a  detectable quantity of the antigen  as 
well as a  greater amount of 6C3 Ag per cell (Table I).  We conclude that  mAb 
6C3  detects  a  normal  cell  antigen  that  becomes  aberrantly  induced  and/or 
amplified during neoplastic transformation  by A-MuLV. 
Furthermore,  A-MuLV-injected  mice  develop  Abelson  disease  and  a  trans- 
formed subpopulation of cells within  their bone marrow bearing high  levels of 
6C3 Ag as well as lymphoid differentiation  markers typical of pre-B cells. The 
surface  differentiation  phenotype  of 6C3Ag  h~  cells  from  an  Abelson-diseased 
mouse depicted in Fig. 4 corresponds to an early pre-B cell stage of differentia- 
tion. In addition, the 6C3Ag  h~ cells present in the bone marrow of diseased mice 
represent  the  transformed  population  of cells, as measured by agar  clonability 
(Fig.  6).  Although just one characteristic of transformation,  agar colony forma- 
tion is a  good measure of autonomous growth capacity. We do not know if the 
increased  expression  of the  antigen  is  a  cause  or  a  consequence  of A-MuLV 
transformation.  We can conclude, though, that the tumor-specific expression of 
the antigen  recognized by mAb 6C3  marks,  specifically, A-MuLV-transformed 
pre-B cells in diseased mice. 
The  transformation-specific  expression  of  the  6C3  Ag  will  allow  further 
investigation of the in vivo neoplastic process. Although it appears that a majority 
of A-MuLV-induced  lymphomas  are  B  lineage  (23),  an  analysis  of all  in  vivo 
tumors has  not been performed.  In  fact,  mAb 6C3  may provide the means to 
study pre-B and  B cell neoplasms from a  variety of sources.  NFS mice injected 
with the Cas-Br-M (NS-1) retroviral complex rapidly develop B lineage lympho- 
mas.  A  tissue-specific increase  in  the  transformation-associated  antigen  recog- 
nized by mAb 6C3 has been documented in all mice analyzed so far (K.  Holmes 
and H. Morse, personal communication),  mAb 6C3 should also prove useful in 
the study of mouse strains genetically susceptible or resistant to A-MuLV-induced 
neoplasia.  Because of the tissue and expression  level specificity of this antigen, 
A-MuLV tumors/mAb 6C3 could also serve as a model system for mAb diagnosis 
and treatment. 
We do not know if the 6C3Ag  h~ cells that appear in lymphomatous mice derive 
directly  from  6C3Ag  ~°  or  6C3  Ag-negative  precursor  cells  during  A-MuLV 
lymphomagenesis.  It is possible that A-MuLV infection induces 6C3 Ag expres- 
sion de novo in lymphoid cells as an inappropriate  expression of what may be a 
stromal cell surface molecule that normally participates in lymphoid progenitor 
cell maturation or proliferation.  On the other hand,  the 6C3Ag  I° subpopulation 
of normal  bone  marrow  cells could  contain  the  A-MuLV  target  cell,  and  A- 
MuLV amplifies antigen expression. Because time course experiments show that 
detectable numbers of 6C3Ag  hi cells do not appear before  10 d after A-MuLV 
infection (data not shown), it is conceivable that a small number of early-infected 
targets express high levels of 6C3 Ag and expand exponentially, or that a larger 
number  of targets  become  infected  and  there  is  a  significant  lag-time  from 
infection to 6C3Ag  h~ expression. The 6C3 Ag phenotype of the A-MuLV target 
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Although amplification of surface 6C3 Ag is independent of M-MuLV alone, 
there is a significant increase in the percentage 6C3Ag  ~° bone marrow cells after 
infection with the helper virus (Table I).  If the 6C3Aghi-transformed cell popu- 
lation derives directly from precursor 6C3Ag  ~° cells, the helper virus may enhance 
tumor production by increasing precursor frequency as  well  as providing the 
necessary viral structural proteins for the A-MuLV genome. Alternatively, it is 
conceivable that bone marrow stromal cells respond to infection with M-MuLV 
by increasing in number and/or expression of 6C3 Ag, thereby amplifying pre- 
B cell generation and the production of A-MuLV target cells.  However, we can 
only conclude with confidence from these experiments that the increase in 6C3 
Ag  observed  in  A-MuLV-infected mice  is  dependent upon  the gag-abl  gene 
product, supplied by the A-MuLV genome and not by the M-MuLV genome. 
Overall, these results substantiate the hypothesis that 6C3Ag  hi expression is an 
inevitable consequence of A-MuLV transformation ofpre-B cells in vivo. Coupled 
with the fact that we have been unable to select mAb 6C3-negative tumor cells 
from A-MuLV-infected in vitro bone marrow cultures or established A-MuLV 
cell lines, these experiments suggest that the gene product recognized by mAb 
6C3 is essential for many B lineage neoplasms. It is unclear ifv-abl or augmented 
c-abl expression is a necessary prerequisite for such 6C3 Ag expression. There- 
fore, a direct examination of the oncogenic potential of 6C3 Ag-encoding genes 
is warranted, as are experiments designed to establish the relationship between 
v-abl or c-abl expression and the 6C3Ag  hl phenotype. 
Summary 
Animals  injected  with  Abelson  murine  leukemia  virus  (A-MuLV)  rapidly 
develop fatal bone marrow-derived lymphosarcomas. In all such diseased animals 
tested, a subpopulation of bone marrow cells expressed a monoclonal antibody- 
defined, B lineage transformation-associated  antigen (6C3 Ag) at levels increased 
from that detected on normal lymphocytes. Cells bearing a  high level of this 
antigen were found to be transformed as measured by clonal growth in agar, 
and they expressed surface antigen markers characteristic of early pre-B cells. 
High-level antigen-expressing cells were found in the bone marrow, lymph nodes, 
and spleen, but never in the thymus of diseased animals. This distribution agrees 
with the published pathology of Abelson disease. 
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